Search

Your search keyword '"Gutiérrez, José María"' showing total 2,255 results
Start Over Author "Gutiérrez, José María"
2,255 results on '"Gutiérrez, José María"'

7. A polygeneric immunogen composed of 22 venoms from sub-Saharan African snakes to expand the neutralization scope of the EchiTAb-plus-ICP antivenom

Author

Sánchez, Andrés, Durán, Gina, Cerdas, Maykel, Gutiérrez, Jairo, Segura, Álvaro, Herrera, María, Vargas, Mariángela, Sánchez, Adriana, Sánchez, Paola, Solano, Gabriela, Villalta, Mauren, Moscoso, Edwin, Umaña, Deibid, Arguedas, Mauricio, Gómez, Aarón, Gutiérrez, José María, and León, Guillermo

Published
2024
Full Text
View/download PDF

11. Pilot-scale evaluation of a dynamic body-feed filtration system for primary clarification of snake antivenoms produced by the caprylic acid method

Author

Sánchez, Andrés, Cerdas, Maykel, Gutiérrez, Jairo, Vargas, Mariángela, Segura, Álvaro, Herrera, María, Chaves-Araya, Stephanie, Sánchez, Ronald, Villalta, Mauren, Durán, Gina, Sánchez, Adriana, Solano, Gabriela, Cordero, Daniel, Sánchez, Paola, Gutiérrez, José María, and León, Guillermo

Published
2024
Full Text
View/download PDF

14. Nomenclature in Palliative and Kidney Supportive Care: Not Just at the End-of-Life

Author

Nitola-Mendoza, Lina, Sánchez-Cárdenas, Miguel, Rodriguez-Chitiva, Néstor, Mora Gutiérrez, José María, Rodriguez-Pena, Rosely, Romero-González, Gregorio, Bleda Pérez, Monserrat, Cuenca Casbas, Paula, Calsina-Berna, Agnès, Álvaro-Pardo, Margarita, Granados Casas, Virginia, Garrido Ballart, Paula, Beroiz Groh, Patricia, Bover, Jordi, Miralles Basseda, Ramón, Leiva-Santos, Juan Pablo, Alonso-Babarro, Alberto, and Julià-Torras, Joaquim

Published
2024
Full Text
View/download PDF

15. Nomenclatura en cuidados paliativos y de soporte renal: no solo al final de la vida

Author

Nitola-Mendoza, Lina, Sánchez-Cárdenas, Miguel, Rodriguez-Chitiva, Néstor, Mora Gutiérrez, José María, Rodriguez-Pena, Rosely, Romero-González, Gregorio, Bleda Perez, Monserrat, Cuenca Casbas, Paula, Calsina Berna, Agnes, Álvaro Pardo, Margarita, Granados Casas, Virginia, Garrido Ballart, Paula, Beroiz Groh, Patricia, Bover, Jordi, Miralles Basseda, Ramón, Leiva-Santos, Juan Pablo, Alonso-Babarro, Alberto, and Julià-Torras, Joaquim

Published
2024
Full Text
View/download PDF

27. Clinical effects of immunization, bleeding, and albumin-based fluid therapy in horses used as immunoglobulin source to produce a polyspecific antivenom (Echitab-plus-ICP) towards venoms of African snakes

Author

Huertas, Rose Mary, Arguedas, Mauricio, Estrada, Juan Manuel, Moscoso, Edwin, Umaña, Deibid, Solano, Gabriela, Vargas, Mariángela, Segura, Álvaro, Sánchez, Andrés, Herrera, María, Villalta, Mauren, Arroyo-Portilla, Cynthia, Gutiérrez, José María, and León, Guillermo

Published
2023
Full Text
View/download PDF

33. Effect of the phospholipase A2 inhibitor Varespladib, and its synergism with crotalic antivenom, on the neuromuscular blockade induced by Crotalus durissus terrificus venom (with and without crotamine) in mouse neuromuscular preparations

Author

de Souza, Jocimar, Oliveira, Isadora C.F., Yoshida, Edson H., Cantuaria, Nathalia M., Cogo, José C., Torres-Bonilla, Kristian A., Hyslop, Stephen, Silva Junior, Nelson J., Floriano, Rafael S., Gutiérrez, José María, and Oshima-Franco, Yoko

Published
2022
Full Text
View/download PDF

34. Progress and Challenges in the Field of Snakebite Envenoming Therapeutics.

Author

Gutiérrez, José María, R. Casewell, Nicholas, and Laustsen, Andreas H.

Subjects
*THERAPEUTIC use of monoclonal antibodies, *DIFFUSION of innovations, *SNAKEBITES, *ANTIVENINS, *SNAKE venom, *SMALL molecules, *RECOMBINANT proteins, *DRUG development
Abstract

Snakebite envenoming kills and maims hundreds of thousands of people every year, especially in the rural settings of tropical regions. Envenomings are still treated with animal-derived antivenoms, which have prevented many lives from being lost but which are also medicines in need of innovation. Strides are being made to improve envenoming therapies, with promising efforts made toward optimizing manufacturing and quality aspects of existing antivenoms, accelerating research and development of recombinant antivenoms based on monoclonal antibodies, and repurposing of small-molecule inhibitors that block key toxins. Here, we review the most recent advances in these fields and discuss therapeutic opportunities and limitations for different snakebite treatment modalities. Finally, we discuss challenges related to preclinical and clinical evaluation, regulatory pathways, large-scale manufacture, and distribution and access that need to be addressed to fulfill the goals of the World Health Organization's global strategy to prevent and control snakebite envenoming. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

35. A supervised machine learning statistical design of experiment approach to modeling the barriers to effective snakebite treatment in Ghana.

Author

Nyarko, Eric, Agyemang, Edmund Fosu, Ameho, Ebenezer Kwesi, Agyekum, Louis, Gutiérrez, José María, and Fernandez, Eduardo Alberto

Subjects
MACHINE learning, SUPERVISED learning, AKAIKE information criterion, STATISTICAL learning, ARTIFICIAL intelligence
Abstract

Background: Snakebite envenoming is a serious condition that affects 2.5 million people and causes 81,000–138,000 deaths every year, particularly in tropical and subtropical regions. The World Health Organization has set a goal to halve the deaths and disabilities related to snakebite envenoming by 2030. However, significant challenges in achieving this goal include a lack of robust research evidence related to snakebite incidence and treatment, particularly in sub-Saharan Africa. This study aimed to combine established methodologies with the latest tools in Artificial Intelligence to assess the barriers to effective snakebite treatment in Ghana. Method: We used a MaxDiff statistical experiment design to collect data, and six supervised machine learning models were applied to predict responses whose performance showed an advantage over the other through 6921 data points partitioned using the hold-back validation method, with 70% training and 30% validation. The results were compared using key metrics: Akaike Information Criterion corrected, Bayesian Information Criterion, Root Average Squared Error, and Fit Time in milliseconds. Results: Considering all the responses, none of the six machine learning algorithms proved superior, but the Generalized Regression Model (Ridge) performed consistently better among the candidate models. The model consistently predicted several key significant barriers to effective snakebite treatment, such as the high cost of antivenoms, increased use of unorthodox, harmful practices, lack of access to effective antivenoms in remote areas when needed, and resorting to unorthodox and harmful practices in addition to hospital treatment. Conclusion: The combination of a MaxDiff statistical experiment design to collect data and six machine learning models allowed the identification of barriers to accessing effective therapies for snakebite envenoming in Ghana. Addressing these barriers through targeted policy interventions, including intensified advocacy, continuous education, community engagement, healthcare worker training, and strategic investments, can enhance the effectiveness of snakebite treatment, ultimately benefiting snakebite victims and reducing the burden of snakebite envenoming. There is a need for robust regulatory frameworks and increased antivenom production to address these barriers. Author summary: Snakebite envenoming, a severe condition, affects 2.5 million people and causes 81,000–138,000 deaths annually, particularly in tropical and subtropical regions of Africa, Asia, and Latin America. The World Health Organization aims to reduce this burden by 50% by 2030. However, significant barriers exist to achieving these targets, especially in Sub-Saharan Africa. These barriers include limited rigorous research evidence and the lack of investment in effective antivenoms for local snake species. Meeting this goal will require innovative research to gather better data on snakebite incidence and treatment. Artificial intelligence is one promising field that can contribute to this effort. For the first time, we have demonstrated how MaxDiff statistical experiment designs and machine learning algorithms can be explored to predict the barriers to effective snakebite treatment, such as the high cost of antivenoms, increased use of harmful practices, lack of access to effective antivenoms in remote areas, and resorting to unorthodox and harmful practices in addition to hospital treatment. Addressing these barriers through targeted policy interventions, including intensified advocacy, continuous education, community engagement, healthcare worker training, and strategic investments, can enhance the effectiveness of snakebite treatment. Robust regulatory frameworks and increased local antivenom production are also needed to address these barriers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Engineered nanoparticles bind elapid snake venom toxins and inhibit venom-induced dermonecrosis.

Author

O'Brien, Jeffrey, Lee, Shih-Hui, Gutiérrez, José María, and Shea, Kenneth J

Subjects
Animals, Mice, Skin Diseases, Snake Bites, Disease Models, Animal, Necrosis, Elapid Venoms, Protein Binding, Toxins, Biological, Nanoparticles, Naja, Hydrogel, Polyethylene Glycol Dimethacrylate, Disease Models, Animal, Hydrogel, Polyethylene Glycol Dimethacrylate, Toxins, Biological, Biological Sciences, Medical and Health Sciences, Tropical Medicine
Abstract

Envenomings by snakebites constitute a serious and challenging global health issue. The mainstay in the therapy of snakebite envenomings is the parenteral administration of animal-derived antivenoms. Significantly, antivenoms are only partially effective in the control of local tissue damage. A novel approach to mitigate the progression of local tissue damage that could complement the antivenom therapy of envenomings is proposed. We describe an abiotic hydrogel nanoparticle engineered to bind to and modulate the activity of a diverse array of PLA2 and 3FTX isoforms found in Elapidae snake venoms. These two families of protein toxins share features that are associated with their common (membrane) targets, allowing for nanoparticle sequestration by a mechanism that differs from immunological (epitope) selection. The nanoparticles are non-toxic in mice and inhibit dose-dependently the dermonecrotic activity of Naja nigricollis venom.

Published
2018

40. Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.

Author

Lewin, Matthew R, Gutiérrez, José María, Samuel, Stephen P, Herrera, María, Bryan-Quirós, Wendy, Lomonte, Bruno, Bickler, Philip E, Bulfone, Tommaso C, and Williams, David J

Subjects
Animals, Mice, Elapidae, Acetates, Indoles, Elapid Venoms, Neurotoxins, Antivenins, Administration, Oral, Female, Male, Phospholipase A2 Inhibitors, PLA2, antivenom, envenoming, field antidote, inhibitor, neglected tropical disease, neurotoxicity, phospholipase A2, snakebite, taipan, Administration, Oral, Biochemistry and Cell Biology, Pharmacology and Pharmaceutical Sciences
Abstract

There is an unmet need for economical snakebite therapies with long shelf lives that are effective even with delays in treatment. The orally bioavailable, heat-stable, secretory phospholipase A₂ (sPLA₂) inhibitor, LY333013, demonstrates antidotal characteristics for severe snakebite envenoming in both field and hospital use. A murine model of lethal envenoming by a Papuan taipan (Oxyuranus scutellatus) demonstrates that LY333013, even with delayed oral administration, improves the chances of survival. Furthermore, LY333013 improves the performance of antivenom even after it no longer reverses neurotoxic signs. Our study is the first demonstration that neurotoxicity from presynaptic venom sPLA2S can be treated successfully, even after the window of therapeutic antivenom has closed. These results suggest that sPLA₂ inhibitors have the potential to reduce death and disability and should be considered for the initial and adjunct treatment of snakebite envenoming. The scope and capacity of the sPLA2 inhibitors ability to achieve these endpoints requires further investigation and development efforts.

Published
2018

44. Engineered nanoparticles bind elapid snake venom toxins and inhibit venom-induced dermonecrosis

Author

O’Brien, Jeffrey, Lee, Shih-Hui, Gutiérrez, José María, and Shea, Kenneth J

Subjects
Medical Biotechnology, Biomedical and Clinical Sciences, Nanotechnology, Bioengineering, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Animals, Disease Models, Animal, Elapid Venoms, Hydrogel, Polyethylene Glycol Dimethacrylate, Mice, Naja, Nanoparticles, Necrosis, Protein Binding, Skin Diseases, Snake Bites, Toxins, Biological, Biological Sciences, Medical and Health Sciences, Tropical Medicine, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Envenomings by snakebites constitute a serious and challenging global health issue. The mainstay in the therapy of snakebite envenomings is the parenteral administration of animal-derived antivenoms. Significantly, antivenoms are only partially effective in the control of local tissue damage. A novel approach to mitigate the progression of local tissue damage that could complement the antivenom therapy of envenomings is proposed. We describe an abiotic hydrogel nanoparticle engineered to bind to and modulate the activity of a diverse array of PLA2 and 3FTX isoforms found in Elapidae snake venoms. These two families of protein toxins share features that are associated with their common (membrane) targets, allowing for nanoparticle sequestration by a mechanism that differs from immunological (epitope) selection. The nanoparticles are non-toxic in mice and inhibit dose-dependently the dermonecrotic activity of Naja nigricollis venom.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results